Evidence
Alzheimers Dement. 2024 Feb 27. doi: 10.1002/alz.13734. Online ahead of print.
ABSTRACT
INTRODUCTION: Alzheimer’s disease (AD) involves the complement cascade, with complement component 3 (C3) playing a key role. However, the relationship between C3 and amyloid beta (Aβ) in blood is limited.
METHODS: Plasma C3 and Aβ oligomerization tendency (AβOt) were measured in 35 AD patients and 62 healthy controls. Correlations with cerebrospinal fluid (CSF) biomarkers, cognitive impairment, and amyloid positron emission tomography (PET) were analyzed. Differences between biomarkers were compared in groups classified by concordances of biomarkers.
RESULTS: Plasma C3 and AβOt were elevated in AD patients and in CSF or amyloid PET-positive groups. Weak positive correlation was found between C3 and AβOt, while both had strong negative correlations with CSF Aβ42 and cognitive performance. Abnormalities were observed for AβOt and CSF Aβ42 followed by C3 changes.
DISCUSSION: Increased plasma C3 in AD are associated with amyloid pathology, possibly reflecting a defense response for Aβ clearance. Further studies on Aβ-binding proteins will enhance understanding of Aβ mechanisms in blood.
PMID:38411315 | DOI:10.1002/alz.13734
Add to Google Keep
Estimated reading time: 3 minute(s)
Latest: Psychiatryai.com #RAISR4D
Cool Evidence: Engaging Young People and Students in Real-World Evidence ☀️
Real-Time Evidence Search [Psychiatry]
AI Research [Andisearch.com]
Subsequent correlated changes in complement component 3 and amyloid beta oligomers in the blood of patients with Alzheimer’s disease
🌐 90 Days
VR Related Evidence Matrix
- Amyloid-β and Phosphorylated Tau are the Key Biomarkers and Predictors of Alzheimer's Disease
- Glymphatic system dysfunction predicts amyloid deposition, neurodegeneration, and clinical progression in Alzheimer's disease
- Associations among plasma, MRI, and amyloid PET biomarkers of Alzheimer's disease and related dementias and the impact of health-related comorbidities in a community-dwelling cohort
- Brain structural indicators of beta-amyloid neuropathology
- Machine learning prediction of future amyloid beta positivity in amyloid-negative individuals
- Machine learning prediction of future amyloid beta positivity in amyloid-negative individuals
- Relationship of plasma biomarkers to digital cognitive tests in Alzheimer's disease
- Comparison of plasma and neuroimaging biomarkers to predict cognitive decline in non-demented memory clinic patients
- Plasma brain-derived tau is an amyloid-associated neurodegeneration biomarker in Alzheimer's disease
- Divergent Associations of Slow-Wave Sleep versus Rapid Eye Movement Sleep with Plasma Amyloid-Beta
- Examining amyloid reduction as a surrogate endpoint through latent class analysis using clinical trial data for dominantly inherited Alzheimer's disease
- Association of CSF biomarkers with MRI brain changes in Alzheimer's disease
- Association of beta-Amyloid, Microglial Activation, Cortical Thickness, and Metabolism in Older Adults Without Dementia
- Abnormal EEG microstates in Alzheimer's disease: predictors of b-amyloid deposition degree and disease classification
- Biomarkers - Part 1
- Pathophysiology characterization of Alzheimer's disease in South China's aging population: for the Greater-Bay-Area Healthy Aging Brain Study (GHABS)
- Utilization of fluid-based biomarkers as endpoints in disease-modifying clinical trials for Alzheimer's disease: a systematic review
- Utilization of fluid-based biomarkers as endpoints in disease-modifying clinical trials for Alzheimer's disease: a systematic review
- Alterations of human CSF and serum-based mitophagy biomarkers in the continuum of Alzheimer disease
- Association of plasma biomarkers of Alzheimer's disease and related disorders with cognition and cognitive decline: The MYHAT population-based study
- Presynaptic density determined by SV2A PET is closely associated with postsynaptic metabotropic glutamate receptor 5 availability and independent of amyloid pathology in early cognitive impairment
- The Relationship of Cerebrospinal Fluid Biomarkers and Cognitive Performance in Frontotemporal Dementia
- Proximity extension assay in cerebrospinal fluid identifies neurofilament light chain as biomarker of neurodegeneration in sporadic cerebral amyloid angiopathy
- Difference of Cerebrospinal Fluid Biomarkers and Neuropsychiatric Symptoms Profiles among Normal Cognition, Mild Cognitive Impairment, and Dementia Patient
- Day-to-day sleep variability with Alzheimer's biomarkers in at-risk elderly
- Targeting terminal pathway reduces brain complement activation, amyloid load and synapse loss, and improves cognition in a mouse model of dementia
- a-Synuclein seed amplification assay detects Lewy body co-pathology in autosomal dominant Alzheimer's disease late in the disease course and dependent on Lewy pathology burden
- Plasma Phosphorylated Tau 231 Increases at One-Year Intervals in Cognitively Unimpaired Subjects
- Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease: The DIAN-TU-001 Randomized Clinical Trial
- Quantitative Brain Amyloid PET
- APOE ε4 carrier status modifies plasma p-tau181 concentrations in cognitively healthy super-seniors
- Long-term elevation of complement factors in cerebrospinal fluid of patients with Borna disease virus 1 (BoDV-1) encephalitis
- Cerebrospinal fluid reference proteins increase accuracy and interpretability of biomarkers for brain diseases
- Donanemab in Japanese Patients with Early Alzheimer's Disease: Subpopulation Analysis of the TRAILBLAZER-ALZ 2 Randomized Trial
- CSF biomarkers of immune activation and Alzheimer's disease for predicting cognitive impairment risk in the elderly
- The relation of a cerebrospinal fluid profile associated with Alzheimer's disease with cognitive function and neuropsychiatric symptoms in sporadic cerebral amyloid angiopathy
- Repetitive head injuries in German American football players do not change blood-based biomarker candidates for CTE during a single season
- Echocardiographic measures of the left heart and cerebrospinal fluid biomarkers of Alzheimer's disease pathology in cognitively intact adults: The CABLE study
- High Contrast PET Imaging of Subcortical and Allocortical Amyloid-β in Early Alzheimer's Disease Using [11C]AZD2184
- Contribution of Global Amyloid-PET Imaging for Predicting Future Cognition in the MEMENTO Cohort
- Comparison of tau spread in people with Down syndrome versus autosomal-dominant Alzheimer's disease: a cross-sectional study
- Blood-Based Biomarkers for Early Alzheimer's Disease Diagnosis in Real-World Settings
- Serum GFAP levels correlate with astrocyte reactivity, post-mortem brain atrophy and neurofibrillary tangles
- Cerebrospinal fluid synaptic biomarker changes in bipolar disorder - A longitudinal case-control study
- Neuropsychiatric symptoms profile and markers of Alzheimer disease-type pathology in patients with Lewy body dementias
- Choriocapillaris reduction accurately discriminates against early-onset Alzheimer's disease
- Whole genome-wide sequence analysis of long-lived families (Long-Life Family Study) identifies MTUS2 gene associated with late-onset Alzheimer's disease
- Present and future of Blood-Based biomarkers of Alzheimer's Disease: Beyond the classics
- Sleep and APOE-ε4 have a synergistic effect on plasma biomarkers and longitudinal cognitive decline in older adults
- Association between retinal microvascular abnormalities and late-life brain amyloid-b deposition: the ARIC-PET study
- Serum and cerebrospinal fluid neurofilament light chain and glial fibrillary acid protein levels in early and advanced stages of cerebral amyloid Angiopathy
- Search for cerebrospinal fluid biomarkers in patients with major psychiatric disorders: Multiplex immunoassay findings and proximity extension assay prospects
- Disentangling Sex-Dependent Effects of APOE on Diverse Trajectories of Cognitive Decline in Alzheimer's Disease
- Search for cerebrospinal fluid biomarkers in patients with major psychiatric disorders: Multiplex immunoassay findings and proximity extension assay prospects
- Search for cerebrospinal fluid biomarkers in patients with major psychiatric disorders: Multiplex immunoassay findings and proximity extension assay prospects
- Cognition and Amyloid-b in Older Veterans: Characterization and Longitudinal Outcomes of Data-Derived Phenotypes
- Cognition and Amyloid-b in Older Veterans: Characterization and Longitudinal Outcomes of Data-Derived Phenotypes
- Neurofilament light chain is elevated in patients with newly diagnosed idiopathic intracranial hypertension: A prospective study
- Early molecular events of autosomal-dominant Alzheimer's disease in marmosets with PSEN1 mutations
- Social relationships, amyloid burden, and dementia: The ARIC-PET study
- In vivo PET classification of tau pathologies in patients with frontotemporal dementia
- Comparison of consistency in centiloid scale among different analytical methods in amyloid PET: the CapAIBL, VIZCalc, and Amyquant methods
- Plasma Leptin and Alzheimer Protein Pathologies Among Older Adults
- Bacteroidota inhibit microglia clearance of amyloid-beta and promote plaque deposition in Alzheimer's disease mouse models
Evidence Blueprint
Subsequent correlated changes in complement component 3 and amyloid beta oligomers in the blood of patients with Alzheimer’s disease
☊ AI-Driven Related Evidence Nodes
(recent articles with at least 5 words in title)
More Evidence
Subsequent correlated changes in complement component 3 and amyloid beta oligomers in the blood of patients with Alzheimer’s disease
🌐 365 Days
VR Related Evidence Matrix
- Associations of the A/T/N profiles in PET, CSF, and plasma biomarkers with Alzheimer's disease neuropathology at autopsy
- Astrocyte biomarkers GFAP and YKL-40 mediate early Alzheimer's disease progression
- Amyloid-β and Phosphorylated Tau are the Key Biomarkers and Predictors of Alzheimer's Disease
- Glymphatic system dysfunction predicts amyloid deposition, neurodegeneration, and clinical progression in Alzheimer's disease
- Biomarkers of Alzheimer's disease and neurodegeneration in dried blood spots-A new collection method for remote settings
- Associations among plasma, MRI, and amyloid PET biomarkers of Alzheimer's disease and related dementias and the impact of health-related comorbidities in a community-dwelling cohort
- Characteristics of discordance between amyloid positron emission tomography and plasma amyloid-β 42/40 positivity
- Association of amyloid-beta with depression or depressive symptoms in older adults without dementia: a systematic review and meta-analysis
- Amyloid and tau-PET in early-onset AD: Baseline data from the Longitudinal Early-onset Alzheimer's Disease Study (LEADS)
- Fully automated measurement of plasma Aβ42/40 and p-tau181: Analytical robustness and concordance with cerebrospinal fluid profile along the Alzheimer's disease continuum in two independent cohorts
- Longitudinal blood biomarker trajectories in preclinical Alzheimer's disease
- Utility of amyloid PET Imaging in a Memory Clinic
- Blood-brain barrier breakdown is linked to tau pathology and neuronal injury in a differential manner according to amyloid deposition
- Longitudinal changes in Alzheimer's-related plasma biomarkers and brain amyloid
- Performance of the Lumipulse plasma Aβ42/40 and pTau181 immunoassays in the detection of amyloid pathology
- Retina pathology as a target for biomarkers for Alzheimer's disease: Current status, ophthalmopathological background, challenges, and future directions
- Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology
- Profiling of plasma biomarkers in the context of memory assessment in a tertiary memory clinic
- CSF 14-3-3β is associated with progressive cognitive decline in Alzheimer's disease
- Alzheimer Disease Biomarkers: Moving from CSF to Plasma for Reliable Detection of Amyloid and tau Pathology
- Blood-based biomarkers in Alzheimer's disease - moving towards a new era of diagnostics
- Can We Use Blood Biomarkers as Entry Criteria and for Monitoring Drug Treatment Effects in Clinical Trials? A Report from the EU/US CTAD Task Force
- Brain structural indicators of beta-amyloid neuropathology
- White matter hyperintensity volume modifies the association between CSF vascular inflammatory biomarkers and regional FDG-PET along the Alzheimer's disease continuum
- Machine learning prediction of future amyloid beta positivity in amyloid-negative individuals
- Machine learning prediction of future amyloid beta positivity in amyloid-negative individuals
- Relationship of plasma biomarkers to digital cognitive tests in Alzheimer's disease
- Associations of cerebrospinal fluid complement proteins with Alzheimer's pathology, cognition, and brain structure in non-dementia elderly
- Comparison of plasma and neuroimaging biomarkers to predict cognitive decline in non-demented memory clinic patients
- Early onset diagnosis in Alzheimer's disease patients via amyloid-β oligomers-sensing probe in cerebrospinal fluid
- Plasma pTau-217 and N-terminal tau (NTA) enhance sensitivity to identify tau PET positivity in amyloid-β positive individuals
- Plasma brain-derived tau is an amyloid-associated neurodegeneration biomarker in Alzheimer's disease
- Plasma Biomarker Strategy for Selecting Patients With Alzheimer Disease for Antiamyloid Immunotherapies
- Divergent Associations of Slow-Wave Sleep versus Rapid Eye Movement Sleep with Plasma Amyloid-Beta
- Effects of the active amyloid beta immunotherapy CAD106 on PET measurements of amyloid plaque deposition in cognitively unimpaired APOE ε4 homozygotes
- Examining amyloid reduction as a surrogate endpoint through latent class analysis using clinical trial data for dominantly inherited Alzheimer's disease
- Investigation of sex differences in mutation carriers of the Dominantly Inherited Alzheimer Network
- CSF p-tau205: a biomarker of tau pathology in Alzheimer's disease
- Levels of Alzheimer's disease blood biomarkers are altered after food intake-A pilot intervention study in healthy adults
- Association of CSF biomarkers with MRI brain changes in Alzheimer's disease
- Profiling amyloid-β peptides as biomarkers for cerebral amyloid angiopathy
- Tear biomarkers for Alzheimer's disease screening and diagnosis (the TearAD study): design and rationale of an observational longitudinal multicenter study
- Multimorbidity, cognitive phenotypes, and Alzheimer's disease plasma biomarkers in older adults: A population-based study
- A pilot study to evaluate the effect of CT1812 treatment on synaptic density and other biomarkers in Alzheimer's disease
- Plasma N-terminal containing tau fragments (NTA-tau): a biomarker of tau deposition in Alzheimer's Disease
- Biomarkers for neurodegeneration impact cognitive function: a longitudinal 1-year case-control study of patients with bipolar disorder and healthy control individuals
- Impact of demographics and comorbid conditions on plasma biomarkers concentrations and their diagnostic accuracy in a memory clinic cohort
- Association of beta-Amyloid, Microglial Activation, Cortical Thickness, and Metabolism in Older Adults Without Dementia
- Abnormal EEG microstates in Alzheimer's disease: predictors of b-amyloid deposition degree and disease classification
- Biomarkers - Part 1
- Prevalence and Clinical Implications of a β-Amyloid-Negative, Tau-Positive Cerebrospinal Fluid Biomarker Profile in Alzheimer Disease
- Extracellular vesicle proteome unveils cathepsin B connection to Alzheimer's disease pathogenesis
- Alzheimer's disease-associated complement gene variants influence plasma complement protein levels
- Pathophysiology characterization of Alzheimer's disease in South China's aging population: for the Greater-Bay-Area Healthy Aging Brain Study (GHABS)
- Harmonization of CSF and imaging biomarkers for Alzheimer's disease: Need and practical applications for genetics studies and preclinical classification
- Associations between liver function and cerebrospinal fluid biomarkers of Alzheimer's disease pathology in non-demented adults: The CABLE study
- Utilization of fluid-based biomarkers as endpoints in disease-modifying clinical trials for Alzheimer's disease: a systematic review
- Utilization of fluid-based biomarkers as endpoints in disease-modifying clinical trials for Alzheimer's disease: a systematic review
- Alterations of human CSF and serum-based mitophagy biomarkers in the continuum of Alzheimer disease
- Association of plasma biomarkers of Alzheimer's disease and related disorders with cognition and cognitive decline: The MYHAT population-based study
- Association between results of an amyloid PET scan and healthcare utilization in individuals with cognitive impairment
- Presynaptic density determined by SV2A PET is closely associated with postsynaptic metabotropic glutamate receptor 5 availability and independent of amyloid pathology in early cognitive impairment
- Comparative evaluation of clinical and cerebrospinal fluid biomarker characteristics in rapidly and non-rapidly progressive Alzheimer's disease
- CRISPR-Powered Aptasensor for Diagnostics of Alzheimer's Disease